• Humacyte (NASDAQ:HUMA) is up ~6% in Friday trading after reporting that a U.S. FDA review of its acellular tissues engineered vessel (ATEV) for vascular trauma is ongoing.
• The news provides a sigh of relief after the company said in August that the agency would need additional time to review the application. The original action date was Aug. 10.
• BTIG analyst Ryan Zimmerman, who rates Humacyte a buy, wrote that the development is a positive sign and "suggests that there is forward progress." And while he expects ATEV will win approval, he added the "timing is difficult to handicap."

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。